ARCHIVES

Ceritinib Demonstrates 58% ORR, 7-month PFS in ALK+ NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: Progress Reported In NCI-FDA Fight Over New Drug Tests, Epidemiology Branch Reorganized

December 12, 1975

Nevins: Duke Administration Did a “Very Good Job” Of Handling The Crisis

April 1, 2011

Dispute At City of Hope Pits Center Against For-Profit Physician Group.

May 28, 2010

In Brief: NCI Holding Up Regional Cooperative Group RFA Until Department Approves New Mechanism

February 27, 1981

NCI Budget Chief John Hartinger Retires.

August 4, 2006

“Inoperable” Prostate Cancer May Be Operable, Curable

April 29, 2005